Latest Articles
FDA Approves Two First-Line Immunotherapies for Endometrial Cancer - Cancer Health Treatment News
FDA Approves Two First-Line Immunotherapies for Endometrial Cancer Cancer Health Treatment News
Published: June 20, 2024, 7 a.m.
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer - Frontiers
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer Frontiers
Published: June 20, 2024, 7 a.m.
Two New Immunotherapy-Chemo Options Approved for Endometrial Cancer - Medpage Today
Two New Immunotherapy-Chemo Options Approved for Endometrial Cancer Medpage Today
Published: June 18, 2024, 7 a.m.
Novel immunotherapy combination approved for endometrial cancer - European Pharmaceutical Review
Novel immunotherapy combination approved for endometrial cancer European Pharmaceutical Review
Published: June 18, 2024, 7 a.m.
Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval - FiercePharma
Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval FiercePharma
Published: June 18, 2024, 7 a.m.
Merck’s Keytruda regimen granted FDA approval to treat endometrial cancer - PMLiVE
Merck’s Keytruda regimen granted FDA approval to treat endometrial cancer PMLiVE
Published: June 18, 2024, 7 a.m.
AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer - Reuters
AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer Reuters
Published: June 17, 2024, 7 a.m.
FDA Expands Durvalumab Label to Endometrial Cancer - Medscape
FDA Expands Durvalumab Label to Endometrial Cancer Medscape
Published: June 17, 2024, 7 a.m.
AstraZeneca lands narrow Imfinzi nod in endometrial cancer. Where’s Lynparza? - FiercePharma
AstraZeneca lands narrow Imfinzi nod in endometrial cancer. Where’s Lynparza? FiercePharma
Published: June 17, 2024, 7 a.m.
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval - Pharmaceutical Technology
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval Pharmaceutical Technology
Published: June 17, 2024, 7 a.m.
Link copied to clipboard!